{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:47:27Z","timestamp":1791002847858,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R13AG071150"],"award-info":[{"award-number":["R13AG071150"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ekir.2024.03.033","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T16:50:59Z","timestamp":1712249459000},"page":"1986-1994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis"],"prefix":"10.1016","volume":"9","author":[{"given":"Nelson","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Havasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Barbachano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.03.033_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib2","first-page":"472","article-title":"A\u00a0modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2024.03.033_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2024.03.033_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","article-title":"Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.03.033_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2024.03.033_bib6","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.03.033_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bmt.2010.234","article-title":"Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006","volume":"46","author":"Gertz","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2024.03.033_bib10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib11","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.03.033_bib12","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2024.03.033_bib13","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Evaluation studies research support, non-U.S. govt","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.03.033_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13023-020-01525-2","article-title":"The amyloidosis forum: a public private partnership to advance drug development in AL amyloidosis","volume":"15","author":"Amyloidosis Forum","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.03.033_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the amyloidosis forum cardiac working group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ekir.2024.03.033_bib17","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1007\/s12325-023-02637-4","article-title":"Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the amyloidosis forum multi-organ system working group","volume":"40","author":"Mauermann","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2024.03.033_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","article-title":"Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the amyloidosis forum HRQOL working group","volume":"14","author":"Rizio","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.ekir.2024.03.033_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s43441-024-00641-6","article-title":"Pathway for development and validation of multi-domain endpoints for amyloid light chain (AL) amyloidosis","author":"Signorovitch","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ekir.2024.03.033_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ackd.2017.10.006","article-title":"Challenges in measuring glomerular filtration rate: a clinical laboratory perspective","volume":"25","author":"Seegmiller","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2024.03.033_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0272-6386(82)80091-7","article-title":"Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate","volume":"2","author":"Bauer","year":"1982","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.03.033_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/TP.0000000000002797","article-title":"Performance of creatinine clearance and estimated GFR in assessing kidney function in living donor candidates","volume":"104","author":"Garg","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.03.033_bib23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ki.1985.205","article-title":"Limitations of creatinine as a filtration marker in glomerulopathic patients","volume":"28","author":"Shemesh","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.03.033_bib24","first-page":"400","article-title":"Discrepancy between circadian rhythms of inulin and creatinine clearance","volume":"120","author":"van Acker","year":"1992","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.03.033_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate. Research support, N.I.H., extramural validation studies","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/ajkd.2001.20628","article-title":"Serum cystatin C concentration as a marker of renal dysfunction in the elderly","volume":"37","author":"Fliser","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.03.033_bib30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/clinchem\/48.6.850","article-title":"Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis","volume":"48","author":"Orlando","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.ekir.2024.03.033_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10157-015-1115-1","article-title":"Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1","volume":"19","author":"Shibata","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2024.03.033_bib32","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/ki.1996.405","article-title":"Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer","volume":"50","author":"Merouani","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.03.033_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.03.033_bib34","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1038\/sj.onc.1205868","article-title":"Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays","volume":"21","author":"De Vos","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ekir.2024.03.033_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-012-1049-2","article-title":"Prognostic significance of serum cystatin C in multiple myeloma","volume":"95","author":"Nuckel","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ekir.2024.03.033_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.2008.000638","article-title":"Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration","volume":"94","author":"Terpos","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2024.03.033_bib37","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.03.033_bib38","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.03.033_bib39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/13506129.2017.1293644","article-title":"Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis","volume":"24","author":"Palladini","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2024.03.033_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-020-00391-2","article-title":"Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients","volume":"10","author":"Visram","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ekir.2024.03.033_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1515\/cclm-2021-0912","article-title":"Prospective urinary albumin\/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients","volume":"60","author":"Basset","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100427","article-title":"Correlation between 24-hour urine protein and random urine protein-creatinine ratio in amyloid light-chain amyloidosis","volume":"4","author":"Mendelson","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.ekir.2024.03.033_bib44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.03.033_bib45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.03.033_bib46","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.03.033_bib47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/j.ajkd.2012.04.010","article-title":"Day-to-day variability in spot urine protein-creatinine ratio measurements","volume":"60","author":"Naresh","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.03.033_bib48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2215\/CJN.02450706","article-title":"Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation","volume":"2","author":"Leung","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.03.033_bib49","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3324\/haematol.2012.079210","article-title":"A\u00a0detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?","volume":"98","author":"Leung","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2024.03.033_bib50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2024.03.033_bib51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.26092","article-title":"Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a mayo cohort","volume":"96","author":"Drosou","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2024.03.033_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040629","article-title":"Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide 124I-p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET\/CT imaging","author":"Martin","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ekir.2024.03.033_bib53","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2215\/CJN.06870909","article-title":"Performance of the cockcroft-gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size","volume":"5","author":"Michels","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.03.033_bib54","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2215\/CJN.02300311","article-title":"Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations","volume":"6","author":"Murata","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.03.033_bib55","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:10:42Z","timestamp":1719997842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924016206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2468024924016206"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.03.033","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}